- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- brivanib (active)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 19
- States / cities
- Duarte, California • Los Angeles, California • Newark, Delaware + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 747
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Lenalidomide, Sorafenib
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Nutley, New Jersey
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Axitinib (AG-013736), Best Supportive Care, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 13
- States / cities
- Berkeley, California • La Jolla, California • Orange, California + 7 more
- Conditions
- Liver Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 20 Years to 90 Years
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Gallbladder Cancer AJCC V7, Stage III Hepatocellular Carcinoma AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Carcinoma
- Interventions
- Durvalumab, Guadecitabine
- Biological · Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Newport Beach, California • Baltimore, Maryland
- Conditions
- Hepatocellular Carcinoma
- Interventions
- DEB-TACE
- Procedure
- Lead sponsor
- Surefire Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 6 more
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Advanced Adult Hepatocellular Carcinoma, BCLC Stage B Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma
- Interventions
- Chinese herbal formulation PHY906, sorafenib tosylate, laboratory biomarker analysis, pharmacological study
- Dietary Supplement · Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Advanced Hepatocellular Carcinoma, HCC, Liver Cancer
- Interventions
- PD-0332991
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Hepatocellular Cancer, Liver Cancer, Liver, Cancer Of, Non-Resectable
- Interventions
- OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two, Checkpoint Inhibitor, Immune
- Drug
- Lead sponsor
- Omega Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • Gainesville, Florida • Chicago, Illinois + 3 more
- Conditions
- Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8, Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8
- Interventions
- Atezolizumab, Bevacizumab, Therapeutic Conventional Surgery
- Biological · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- intravenous T900607-sodium
- Drug
- Lead sponsor
- Tularik
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 11
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Interventions
- doxorubicin, bortezomib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
- Interventions
- elzovantinib (TPX-0022)
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 12
- States / cities
- La Jolla, California • Orange, California • Denver, Colorado + 8 more
- Conditions
- Cirrhosis, Hepatitis C, Hepatocellular Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Interventions
- sorafenib tosylate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Memantine Hydrochloride, Bevacizumab, Atezolizumab
- Drug
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Fairfax, Virginia • Falls Church, Virginia
- Conditions
- Liver Cancer
- Interventions
- bevacizumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hepatocellular Carcinoma, HCC, Hepatitis C, HCV
- Interventions
- Automated reminders, Patient navigation
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Child-Pugh Class A, Child-Pugh Class B, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Transarterial Chemoembolization
- Other · Radiation · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)
- Drug · Other · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 24
- States / cities
- Costa Mesa, California • La Jolla, California • Orange, California + 19 more
- Conditions
- Liver Cancer
- Interventions
- yttrium Y 90 glass microspheres
- Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois